154
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Risk factors for FEV1 decline in mild COPD and high-risk populations

, , , , , , , , & show all
Pages 435-442 | Published online: 27 Jan 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yu Pu, Xiuxiu Zhou, Di Zhang, Yu Guan, Yi Xia, Wenting Tu, Yang Lu, Weidong Zhang, Chi-Cheng Fu, Qu Fang, Geertruida H de Bock, Shiyuan Liu & Li Fan. (2022) Re-Defining High Risk COPD with Parameter Response Mapping Based on Machine Learning Models. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2471-2483.
Read now
Rogelio Perez-Padilla, Fernando C Wehrmeister, Maria Montes de Oca, Maria Victorina Lopez, Jose R Jardim, Adriana Muiño, Gonzalo Valdivia & Ana Maria B Menezes. (2018) Outcomes for symptomatic non-obstructed individuals and individuals with mild (GOLD stage 1) COPD in a population based cohort. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3549-3561.
Read now

Articles from other publishers (9)

Masaru Suzuki, Isao Matsumoto, Masato Ishida, Yoshiharu Horie, Hideyuki Ban, Wataru Takeuchi, Shunki Nakagawa, Tohru Nakagawa, Tetsuhisa Kitamura & Shigeo Muro. (2023) Investigation of time profile of FEV1 across the onset of potential COPD: a retrospective cohort study using medical checkup data in Japan. Scientific Reports 13:1.
Crossref
Akhilesh Jha, Tom Ward, Steven Walker, Amanda T Goodwin & James D Chalmers. (2022) Review of the British Thoracic Society Winter Meeting 2021, 24–26 November 2021. Thorax 77:10, pages 1030-1035.
Crossref
Aldana Rosso, Karl Egervall & Sölve Elmståhl. (2022) Annual decline rate in FEV1s in community-dwelling older adults diagnosed with mild to moderate COPD. npj Primary Care Respiratory Medicine 32:1.
Crossref
Rui Lv, Mengyao Xie, Huaqian Jin, Pingping Shu, Mingli Ouyang, Yanmao Wang, Dan Yao, Lehe Yang, Xiaoying Huang & Yiran Wang. (2022) A Preliminary Study on the Relationship Between High-Resolution Computed Tomography and Pulmonary Function in People at Risk of Developing Chronic Obstructive Pulmonary Disease. Frontiers in Medicine 9.
Crossref
Dejan Radovanovic, Marco Contoli, Fulvio Braido, Mauro Maniscalco, Claudio Micheletto, Paolo Solidoro, Pierachille Santus & Mauro Carone. (2022) Future Perspectives of Revaluating Mild COPD. Respiration 101:7, pages 688-696.
Crossref
Hye Jung Park, Sung-Ryeol Kim, Sinae Kim, Hye Sun Lee, Bo Yeon Kim, Hye Kyoung Kim, Sang In Ahn, Ji Hyeon Shin, Jae-Hyun Lee & Jung-Won Park. (2021) Influence of government-driven quality assessment program on patients with chronic obstructive pulmonary disease. Respiratory Research 22:1.
Crossref
Yu-En Hsu, Szu-Chia Chen, Jiun-Hung Geng, Da-Wei Wu, Pei-Yu Wu & Jiun-Chi Huang. (2021) Obesity-Related Indices Are Associated with Longitudinal Changes in Lung Function: A Large Taiwanese Population Follow-Up Study. Nutrients 13:11, pages 4055.
Crossref
Dave Singh, Anthony D. D’Urzo, James F. Donohue & Edward M. Kerwin. (2019) Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. Respiratory Research 20:1.
Crossref
Jose Luis Lopez-Campos, Laura Carrasco Hernández, Xavier Muñoz, Víctor Bustamante & Esther Barreiro. (2018) Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology 23:9, pages 818-827.
Crossref